Severe Acute Respiratory Syndrome–Related Coronavirus Is Inhibited by Interferon‐α
The Journal of Infectious Diseases2004Vol. 189(7), pp. 1164–1167
Citations Over TimeTop 10% of 2004 papers
Ute Ströher, Antonino Di, Yan Li, James E. Strong, Fred Y. Aoki, Frank Plummer, Steven J.M. Jones, Heinz Feldmann
Abstract
Current treatment schemes for severe acute respiratory syndrome (SARS) include broad-spectrum antibiotics, glucocorticoids, and ribavirin. We evaluated the susceptibility of the SARS-related coronavirus (SARS CoV) to ribavirin and interferon (IFN)- alpha in vitro by use of cytopathic effect, plaque assay, and immunoblot analysis. Ribavirin did not inhibit viral growth at concentrations attainable in human serum. In contrast, IFN- alpha showed an in vitro inhibitory effect starting at concentrations of 1000 IU/mL. In conclusion, ribavirin alone is unlikely to be beneficial in the prophylaxis or treatment of SARS CoV infections. Clinical trials with IFN- alpha might be justified to determine a beneficial effect on the outcome of SARS.
Related Papers
- Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro.(2005)
- → Treatment considerations for coronavirus (COVID-19)(2020)13 cited
- → Potential pathogenesis of severe acute respiratory syndrome coronavirus 2.(2020)1 cited
- → Current Update of Severe Acute Respiratory Syndrome Coronavirus 2(2023)